Nauset Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nauset Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$75K	Buy	+460	New	+$70.1K	0.06%	95

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nauset Wealth Management's ALNY Position: Q1 2022 in Review

Nauset Wealth Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2022: 460 shares worth $75K. The stake represents 0.06% of the portfolio and ranks #95 among its holdings.

444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

Nauset Wealth Management held 460 shares of Alnylam Pharmaceuticals worth $75K as of Q1 2022.
Alnylam Pharmaceuticals was a new Nauset Wealth Management position in Q1 2022.
Alnylam Pharmaceuticals made up 0.06% of Nauset Wealth Management's portfolio in Q1 2022, its #95 holding.
444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Nauset Wealth Management's 13F filing for Q1 2022, filed 28 Apr 2022.